Cabozantinib or XL-184 is a tyrosine kinase (c-MET, VEGFR2) inhibitor. It has been shown to reduce tumor growth, metastasis, angiogenesis, and induce apoptosis.
Yakes FM, Chen J, Tan J, et al. Mol Cancer Ther. 10:2298-308 (2011).
Agarwal N, Sonpavde G, Sternberg CN. Eur Utol 61:950-60 (2012).
